مباشر

Endpoints NewsAmgen stands by rare disease drug Tavneos amid Japan liver toxicity report Endpoints NewsFDA's unreleased Covid vaccine deaths report is published by lawmaker 10x Genomics NewsThe 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call - Yahoo Finance BioWorldMoney raised by biopharma BioWorldBiopharma money raised: Jan. 1-May 15, 2026 BioPharma DiveFDA approves AstraZeneca’s new kind of hypertension drug BioWorldAuthorities work to quickly sequence Ebola species in latest outbreak BioPharma DiveMerck ADC, licensed from China, hits mark in first big global trial Boston ScientificBoston Scientific buys $1.5B stake in TAVR developer MiRus - MedTech Dive Endpoints NewsRegeneron reaches $125M Parabilis deal for hard-to-catch drug targets FierceBiotechBioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal FierceBiotechAfter rare disease flop, cash-strapped Quince finds salvation in reverse merger

Endpoints News ١٨ مايو ٢٠٢٦

Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule

An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipe...

An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the patent cliff for its best-selling ...